Siegall has been CEO of Seagen for two decades, taking the helm of the company four years after co-founding it in 1998, and building it into a biotech bellwether with four drugs on the market and ...

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ( ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...

The "Refractory Metastatic Melanoma - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The report provides comprehensive insights about 4+ companies and 4+ ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of ...

Pfizer's planned debt sale this week, to help fund its acquisition of rival drugmaker Seagen, will rank among the largest individual corporate bond sales in U.S. history. In a filing with the U.S ...

NEW YORK: Pfizer Inc’s proposed US$43bil (RM195bil) takeover of Seagen Inc will face an investigation from the European Union’s (EU) merger enforcer, as the bloc continues to scrutinise large ...

In 2023, Pfizer paid $43 billion to acquire Seagen, a large biopharma company focused on cancer treatments. That acquisition has given management confidence that it can produce as many as eight ...

Recently, Pfizer has concentrated on expanding its oncology segment, enhanced by the March 2023 acquisition of Seagen. This focus on oncology highlights the importance of research and development ...

Detailed price information for Verizon Communications Inc (VZ-N) from The Globe and Mail including charting and trades.